Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  10,882 results for ""GLUCAGON-like peptides""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice.

  • Authors : Forny Germano L; Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, M5G1X5, Canada.; Koehler JA

Subjects: Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/pharmacology ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/therapeutic use ; Alzheimer Disease*/Alzheimer Disease*/Alzheimer Disease*/drug therapy

  • Source: Molecular metabolism [Mol Metab] 2024 Nov; Vol. 89, pp. 102019. Date of Electronic Publication: 2024 Aug 30.Publisher: Elsevier GmbH Country of Publication: Germany NLM ID: 101605730 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

[The GLP-1 analogue battle: effects of semaglutide 0,5 mg/weekly versus liraglutide 3 mg/daily on anthropometric parameters after 3 months in a real world-scenario].

  • Authors : Pujol Calafat A; Servicio de Endocrinología y Nutrición. Hospital Universitario de Son Llátzer.; Nicolau J

Subjects: Liraglutide*/Liraglutide*/Liraglutide*/therapeutic use ; Liraglutide*/Liraglutide*/Liraglutide*/administration & dosage ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/administration & dosage

  • Source: Nutricion hospitalaria [Nutr Hosp] 2024 Dec 19; Vol. 41 (6), pp. 1224-1230.Publisher: Grupo Aran Country of Publication: Spain NLM ID: 9100365 Publication Model: Print Cited Medium: Internet ISSN: 1699-5198 (Electronic)

Record details

Connect Read More Add to Saved list
×
Academic Journal

[Impact of Elon Musk's statements on the use of semaglutide in the Lazio Region: a time series analysis study.]

  • Authors : Belleudi V; Dipartimento di epidemiologia Asl Roma 1, Ssr Lazio.; Lopes S

Subjects: Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/therapeutic use ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/administration & dosage ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy

  • Source: Recenti progressi in medicina [Recenti Prog Med] 2024 Dec; Vol. 115 (12), pp. 593-598.Publisher: Il Pensiero Scientifico Editore Country of Publication: Italy NLM ID: 0401271 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.

  • Authors : Berra C; Department of Endocrinology and Metabolic Diseases, IRCCS Multimedica, Milan, Italy. Electronic address: .; Manfrini R

Subjects: Immunoglobulin Fc Fragments*/Immunoglobulin Fc Fragments*/Immunoglobulin Fc Fragments*/therapeutic use ; Immunoglobulin Fc Fragments*/Immunoglobulin Fc Fragments*/Immunoglobulin Fc Fragments*/adverse effects ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy

  • Source: Pharmacological research [Pharmacol Res] 2024 Dec; Vol. 210, pp. 107517. Date of Electronic Publication: 2024 Nov 28.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8907422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Time-Efficacy Relationship of Semaglutide in the Treatment of Type 2 Diabetes Mellitus: A Model-Based Meta-Analysis.

  • Authors : Zhang K; School of Mathematics and Computing Science, Guangxi Colleges and Universities Key Laboratory of Data Analysis and Computation, Guilin University of Electronic Technology, Jinji Road No 1, Qixing District, Guilin, 541004, China.; Center for Applied Mathematics of Guangxi (GUET), Jinji Road No 1, Qixing District, Guilin, 541004, China.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/blood ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/administration & dosage

  • Source: Clinical pharmacokinetics [Clin Pharmacokinet] 2024 Dec; Vol. 63 (12), pp. 1679-1688. Date of Electronic Publication: 2024 Nov 16.Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1926

Record details

Read More Add to Saved list
×
Academic Journal

Exploring the antioxidant properties of semaglutide: A comprehensive review.

  • Authors : Yaribeygi H; Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran. Electronic address: .; Maleki M

Subjects: Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/therapeutic use ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/pharmacology ; Antioxidants*/Antioxidants*/Antioxidants*/therapeutic use

  • Source: Journal of diabetes and its complications [J Diabetes Complications] 2024 Dec; Vol. 38 (12), pp. 108906. Date of Electronic Publication: 2024 Nov 12.Publisher: Elsevier Science Pub. Co Country of Publication: United States NLM ID: 9204583 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Semaglutide as a possible therapy for healthy aging: Targeting the hallmarks of aging.

  • Authors : Ortiz GU; Department of Health Sciences, Ribeirão Preto Medical School, University of São Paulo, USP, Ribeirão Preto, São Paulo, Brazil.; de Freitas EC

Subjects: Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/therapeutic use ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/pharmacology ; Oxidative Stress*/Oxidative Stress*/Oxidative Stress*/drug effects

  • Source: Ageing research reviews [Ageing Res Rev] 2024 Dec; Vol. 102, pp. 102582. Date of Electronic Publication: 2024 Nov 14.Publisher: Elsevier Science Country of Publication: England NLM ID: 101128963 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Real world effectiveness of oral semaglutide: Focus on patients with type 2 diabetes older than 75 years.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/blood ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/therapeutic use

  • Source: Diabetes research and clinical practice [Diabetes Res Clin Pract] 2024 Dec; Vol. 218, pp. 111928. Date of Electronic Publication: 2024 Nov 12.Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8508335 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: A retrospective single center observational study.

  • Authors : Santos LB; Department of Anesthesiology - São Luiz Hospital - Itaim/Rede D'Or - CMA Anesthesia Team, São Paulo, Brazil; Rede D'Or, D'Or Institute for Research and Education (IDOR), São Paulo, Brazil. Electronic address: .

Subjects: Endoscopy, Digestive System* ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/administration & dosage ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/adverse effects

  • Source: Journal of clinical anesthesia [J Clin Anesth] 2024 Dec; Vol. 99, pp. 111668. Date of Electronic Publication: 2024 Oct 30.Publisher: Elsevier Country of Publication: United States NLM ID: 8812166 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

REAL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: Ambispective, multicenter clinical study. Results in the GLP1-experienced cohort.

  • Authors : Cárdenas-Salas JJ; Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, CP 28040 Madrid, Madrid, Spain; Hospital Universitario Infanta Elena, Avda. Reyes Católicos 21, CP 28340 Valdemoro, Madrid, Spain

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/blood ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/administration & dosage

  • Source: Journal of diabetes and its complications [J Diabetes Complications] 2024 Dec; Vol. 38 (12), pp. 108874. Date of Electronic Publication: 2024 Sep 17.Publisher: Elsevier Science Pub. Co Country of Publication: United States NLM ID: 9204583 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
  • 1-10 of  10,882 results for ""GLUCAGON-like peptides""